Matthew Caufield

Stock Analyst at HC Wainwright & Co.

(0.97)
# 3,736
Out of 4,886 analysts
122
Total ratings
28.69%
Success rate
-24.78%
Average return

Stocks Rated by Matthew Caufield

Opus Genetics
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.06
Upside: +654.72%
Ardelyx
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $4.48
Upside: +123.21%
Mineralys Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $42
Current: $13.95
Upside: +201.08%
Lyra Therapeutics
Jun 10, 2025
Maintains: Neutral
Price Target: $2$16
Current: $9.25
Upside: +72.97%
Phathom Pharmaceuticals
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $9.02
Upside: +121.73%
Akebia Therapeutics
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $3.71
Upside: +115.63%
DiaMedica Therapeutics
May 29, 2025
Reiterates: Buy
Price Target: $10
Current: $3.65
Upside: +173.97%
Unity Biotechnology
May 27, 2025
Downgrades: Neutral
Price Target: $4$2
Current: $0.20
Upside: +899.50%
Tarsus Pharmaceuticals
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $39.68
Upside: +81.45%
Aldeyra Therapeutics
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $4.33
Upside: +131.21%
Reiterates: Buy
Price Target: $30
Current: $9.93
Upside: +202.11%
Reiterates: Buy
Price Target: $30
Current: $2.40
Upside: +1,150.00%
Reiterates: Buy
Price Target: $32
Current: $8.29
Upside: +286.01%
Reiterates: Buy
Price Target: $38
Current: $31.32
Upside: +21.33%
Reiterates: Buy
Price Target: $10
Current: $0.83
Upside: +1,105.98%
Reiterates: Buy
Price Target: $12
Current: $0.61
Upside: +1,882.49%
Reiterates: Neutral
Price Target: $2
Current: $2.04
Upside: -1.96%
Reiterates: Neutral
Price Target: $3
Current: $3.88
Upside: -22.68%
Downgrades: Neutral
Price Target: $12$2
Current: $3.41
Upside: -41.35%
Reiterates: Buy
Price Target: $36
Current: $4.22
Upside: +753.08%
Reiterates: Buy
Price Target: $28
Current: $286.36
Upside: -90.22%